Clinical trials: Cancer of Stomach
Early Gastric Cancer, Gastric Adenoma
Fibrin Glue After ESD for High Risk Patients of Bleeding
It is a prospective randomized controlled study to look for effectiveness of fibrin glue to prevent bleeding in high-risk patients after endoscopic submucosal dissection in gastric neoplasm.
- Trial name
- NCT04602689
- Testing
- Human fibrinogen concentrate
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Seoul National University Hospital
Gastric Cancer
Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer
The aim of this study to validate the role of pepsinogens in gastric cancer screening.
- Trial name
- NCT06301464
- Where
- South Korea
- Volunteers
- 24,000 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
HER2-expressing Cancers
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable)…
- Trial name
- NCT02892123
- Testing
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Jazz Pharmaceuticals
Metabolic Syndrome, Gastric Cancer
A Metabolomics-based Study to Explore the Mechanism of Remission of Metabolic Syndrome After Radical Gastrectomy
1. Analysis of preoperative and postoperative metabolite changes: Through metabolomics technology, the changes of preoperative and postoperative metabolites in patients with gastric cancer complicated with metabolic syndrome were…
- Trial name
- Metabolomics (NCT06707714)
- Testing
- hypertension, diabetes, fatty liver
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Dong Peng
Immunotherapy Gastrict Cancer, Inflammation Biomarkers
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.
- Conditions
- Immunotherapy Gastrict Cancer, Inflammation Biomarkers, Gastric Cancers
- Trial name
- NCT06706466
- Testing
- observational study
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Chang-Ming Huang, Prof.
Gastric Cancer
The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis
To investigate the impact of the number of mesogastria containing metastatic lymph nodes on the prognosis of gastric cancer.
- Trial name
- NCT06697821
- Testing
- D2＋CME
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Jichao Qin
Gastric Carcinoma, Gastric Neoplasm
The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced Gastric Cancer
Compared with other anti-tumor drugs, immune checkpoint inhibitors (ICIs) have their own unique pharmacokinetics (PK) and pharmacodynamics (PD), and affect patient clinical outcomes.
- Conditions
- Gastric Carcinoma, Gastric Neoplasm, Gastric (cardia, Body) Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT06702683
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Lin Liu
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Colorectal Cancer, Stomach Disease
Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
1. The abundant results from this trial will be helpful for assessing the feasibility of increasing stool sampling and shortening screening interval in population setting for lower and upper gastrointestinal tract lesions, their…
- Trial name
- NCT01741363
- Testing
- FIT(Eiken OC-Sensor) Two-day sampling, FIT(Eiken OC-Sensor) One-year interval, FIT(Eiken OC-Sensor) One-day sampling
- Where
- Taiwan
- Volunteers
- 99,314 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Gastric Cancer
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
Multicentric, exploratory, non-pharmacologic, retrospective/prospective, translational study aiming to identify the molecular, cellular and psychological-sociological variables predictive of response to chemotherapy in gastric…
- Trial name
- GRAMMY (NCT04842916)
- Where
- 5 sites in France, Greece and 1 more
- Volunteers
- 250 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens
This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-expressing advanced gastric or GEJ adenocarcinoma who have received at least 2 prior…
- Trial name
- DG-06 (NCT04989816)
- Testing
- Trastuzumab Deruxtecan
- Where
- 24 sites in China
- Volunteers
- 95 people
- Sponsor
- AstraZeneca
Gastric Cancer
Validation of a Model for Predicting Anastomotic Leakage
This study will validate a machine learning model for predicting anastomotic leakage of esophagogastrostomy and esophagojejunostomy.
- Trial name
- NCT05646290
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Jichao Qin
Gastric Cancer
Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC
he present study retrospectively analyzed the clinicopathological data of 524 patients diagnosed with LAGC who underwent D2 radical gastrectomy after NACT between January 2010 and December 2021 at 2 centers.
- Trial name
- NCT06696963
- Where
- China
- Volunteers
- 524 people
- Sponsor
- Fujian Medical University
Gastric Cancer
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Evaluating the efficacy and safety of irinotecan liposome injection in combination with Sintilimab in the second-line treatment of progressive gastric cancer
- Trial name
- NCT06697366
- Testing
- Irinotecan liposome injection Ⅱ, Sintilimab
- Volunteers
- 27 people
- Sponsor
- Ruijin Hospital
Gallstones, Gastric Cancer
The Incidence of Gallstones After Gastric Cancer Surgery
Through previous clinical observations and literature, we found that the incidence of gallstones in patients after gastric cancer radical resection was significantly higher than that in the normal population (4%).
- Trial name
- NCT04250402
- Testing
- Resection
- Where
- 2 sites in China
- Volunteers
- 1,019 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Gallstone, Gastric Cancer
The Incidence of Gallstones After Gastrectomy
To provide preventive and therapeutic strategies for participants with gallstones after gastric cancer by comparing the risk of postoperative gallbladder stone formation with two different resection ranges using the Roux-en-Y…
- Trial name
- NCT05965466
- Testing
- Distal gastrectomy and radical resection, Total gastrectomy and radical resection
- Where
- 2 sites in China
- Volunteers
- 531 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Neoplasms
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
- Trial name
- NCT05712889
- Testing
- VIP236 (Q3W), VIP236 (Q2W)
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Vincerx Pharma, Inc.
Gastric Cancer, GastroEsophageal Cancer
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic…
- Trial name
- NCT04281576
- Testing
- NovoTTF-100L(P), Oxaliplatin, Capecitabine
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- NovoCure Ltd.
Anastomotic Leak, Gastric Cancer
Anastomotic Leak Testing in Gastrectomy
Anastomotic leak after radical gastrectomy is a serious complication. Intraoperative leak testing was often used to assess the integrity of the anastomosis.
- Conditions
- Anastomotic Leak, Gastric Cancer, Surgery, Testing, Reality
- Trial name
- NCT04292496
- Testing
- Introperative leak testing
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Nanchong Central Hospital